Menu

  • Electrophysiology
  • Therapies & Procedures
  • Patient Care Portfolio
  • Reimbursement
  • Education & Training

    • The Medtronic AF advantages across our portfolio

    • Increase the accurate and timely diagnosis of AF1
    • Improve AF patient outcomes2–5
    • May reduce AF-related use of healthcare resources3,6
    • Use the LINQ™ family of ICMs (Reveal LINQ™ ICM and LINQ II™ ICM) to make data-guided management decisions such as medical management, including anticoagulation7–10

    Detect AF

    Timely and accurate AF detection and monitoring through device-based algorithms

    LINQ™ family of ICMs 

    LINQ™ ICMs provide data that enables clinicians to objectively diagnose and monitor both asymptomatic and symptomatic AF.11

    This data results in the measure of true AF burden and enables data-driven decisions, including those related to medications and treatments such as anticoagulants or ablation.7–10

    To view the indications, safety, and warnings, scroll down or click on one of the links below to jump you down the page to that product.

    LINQ II™ ICM ISW

    Brief statement for LINQ II™ insertable cardiac monitor system (ICM) and accessories

    Indications

    The LINQ II™ ICM is an insertable automatically activated and patient-activated monitoring system that records subcutaneous ECG and is indicated in adult patients, and in pediatric patients who are at least two years old, in the following cases:

    • Patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
    • Patients who experience transient symptoms such as dizziness, palpitation, syncope, and chest pain that may suggest a cardiac arrhythmia

    Contraindications

    There are no known contraindications for the insertion of the LINQ II™ ICM or its accessories. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically inserted device can be tolerated.

    Warnings and precautions

    Patients with the LINQ II™ ICM should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the medical procedure and EMI warnings, precautions, and guidance manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the LINQ II™ MRI technical manual.

    Accessories available for use with LINQ II™ ICM may experience connectivity or performance issues.  See product manuals for details and troubleshooting instructions.

    Potential adverse events or potential complications

    Potential adverse events from the LINQ II™ ICM include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.

    There are no known adverse events associated with the use of any LINQ II™ ICM accessory.  

    See the device manuals for detailed information regarding the implant procedure, indications / intended use, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 800-328-2518 (technical services) or 800-551-5544 (patient services).

    Caution: Federal law (United States) restricts prescription devices to sale by or on the order of a physician.

    Brief statement for AccuRhythm™ AI ECG classification system

    Intended use

    The intended use of the system is to reduce false positive cardiac arrhythmia episodes.

    Contraindications

    There are no known contraindications for AccuRhythm™ AI Models ZA400, ZA410, or ZA420.

    Precautions

    The AccuRhythm™ AI ECG classification system may incorrectly adjudicate a true positive episode as an AI false episode, causing that episode to be suppressed in the remote monitoring system.

    See the device manual for detailed information regarding the intended use, contraindications, warnings, precautions, and potential complications/adverse events. For further information, call Medtronic technical services at 800-328-2518.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    MAJ_83662

    Reveal LINQ™ ICM ISW

    Brief statement for Reveal LINQ™ insertable cardiac monitor (ICM) system and accessories

    Indications

    The Reveal LINQ™ insertable cardiac monitor (ICM) is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:

    • patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
    • patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain, that may suggest a cardiac arrhythmia.

    The device has not been tested specifically for pediatric use.

    Contraindications

    There are no known contraindications for the implant of the Reveal LINQ™ ICM or its accessories. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically implanted device can be tolerated.

    Warnings and precautions

    Patients with the Reveal LINQ™ ICM should avoid sources of diathermy, high sources of radiation, electrosurgical cautery, external defibrillation, lithotripsy, therapeutic ultrasound and radiofrequency ablation to avoid electrical reset of the device, and/or inappropriate sensing as described in the Medical procedure and EMI precautions manual. MRI scans should be performed only in a specified MR environment under specified conditions as described in the Reveal LINQ™ MRI technical manual. 

    Accessories available for use with Reveal LINQ™ ICM may experience connectivity or performance issues. See product manuals for details and troubleshooting instructions.

    Potential adverse events or potential complications

    Potential complications of the Reveal LINQ device include, but are not limited to, device rejection phenomena (including local tissue reaction), device migration, infection, and erosion through the skin.  

    There are no known adverse events associated with the use of any Reveal LINQ™ ICM accessory.

    See the device manuals for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events.  For further information, please call Medtronic at (800) 328-2518 (Technical Services) or (800) 551-5544 (Patient Services).

    Caution: Federal law (United States) restricts prescription devices to sale by or on the order of a physician.

    AccuRhythm™ AI ECG classification system brief statement

    Intended use

    The intended use of the system is to reduce false positive cardiac arrhythmia episodes.

    Contraindications

    There are no known contraindications for AccuRhythm™ AI Models ZA400, ZA410, or ZA420.

    Precautions

    The AccuRhythm™ AI ECG classification system may incorrectly adjudicate a true positive episode as an AI false episode, causing that episode to be suppressed in the remote monitoring system.

    See the device manual for detailed information regarding the intended use, contraindications, warnings, precautions, and potential complications / adverse events.  For further information, call Medtronic Technical Services at (800) 328-2518.

    Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.

    MAJ_83854

      

    Highest published detection accuracy of 95–96% episode PPV12–14

    Azure™ XT DR MRI pacemaker

    Percepta™ Quad CRT-P MRI

    Cobalt™ XT DR ICD and CRT-D
    Cobalt™ DR ICD and CRT-D

    Cobalt™ XT VR ICD
    Cobalt™ VR ICD

    Using the TruAF™ detection algorithm, Medtronic single-chamber implantable cardioverter defibrillators (ICDs) are the only ICDs that can detect AF with a traditional lead.

    • 34% of patients had AF detected at six months.15

    Watch as Dr. Alan Cheng discusses the importance of AF detection in a single-chamber ICD.

    Dr. Alan Cheng AF detection video

    Watch as Dr. Alan Cheng discusses the importance of AF detection in a single-chamber ICD.

    Reduce AF

    Exclusive algorithms demonstrated to reduce the risk and duration of AF

    Managed Ventricular Pacing (MVP™)

    Reduces unnecessary RV pacing by 99%16

    • Every 1% of unnecessary RV pacing is accompanied by a 1% greater AF risk.17

    Reactive ATP™ algorithm

    Reduces the duration of AT/AF18

    • ≥ 1 day by 19%
    • ≥ 7 days by 36%
    • ≥ 30 days by 44%

    AdaptivCRT™ algorithm

    46% reduction in AF risk19

    The Reactive ATP™ (rATP) algorithm delivers atrial antitachycardia pacing (ATP) to terminate an ongoing AF episode after a programmed interval, or when the rhythm organizes and/or slows. Recent evidence shows rATP reduces the likelihood of patients experiencing AT/AF.18 Learn more in this informative video as CRHF Chief Medical Officer, Dr. Rob Kowal, discusses the data.

    To view the indications, safety, and warnings, scroll down or click on one of the links below to jump you down the page to that product.

    Implantable Pulse Generators (IPG) ISW

    Brief statement: Medtronic IPG

    Indications

    Implantable Pulse Generators (IPGs) are indicated for rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in activity and increases in activity. Pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony, which include various degrees of AV block to maintain the atrial contribution to cardiac output and VVI intolerance (e.g., pacemaker syndrome) in the presence of persistent sinus rhythm. See device manuals for the accepted patient conditions warranting chronic cardiac pacing. Antitachycardia pacing (ATP) is indicated for termination of atrial tachyarrythmias in patients with one or more of the above pacing indications.

    MRI SureScan IPGs: A complete SureScan pacing system is required for use in the MR environment and includes a Medtronic SureScan device connected to Medtronic SureScan Leads.

    Contraindications

    IPGs are contraindicated for concomitant implant with another bradycardia device and concomitant implant with an implantable cardioverter defibrillator. There are no known contraindications for the use of pacing as a therapeutic modality to control heart rate. The patient's age and medical condition, however, may dictate the particular pacing system, mode of operation, and implant procedure used by the physician. Rate-responsive modes may be contraindicated in those patients who cannot tolerate pacing rates above the programmed Lower Rate. Dual chamber sequential pacing is contraindicated in patients with chronic or persistent supraventricular tachycardias, including atrial fibrillation or flutter. Asynchronous pacing is contraindicated in the presence (or likelihood) of competition between paced and intrinsic rhythms. Single chamber atrial pacing is contraindicated in patients with an AV conduction disturbance. Antitachycardia pacing (ATP) therapy is contraindicated in patients with an accessory antegrade pathway. Medtronic Kappa™ 400 Series pacemakers are contraindicated for use with epicardial leads and with abdominal implantation.

    Warnings and precautions

    Changes in a patient's disease and/or medications may alter the efficacy of the device's programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.

    MRI SureScan IPGs only: No lead extenders, lead adaptors or abandoned leads present; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history; the device must be operating within the projected service life, and the system must be implanted in the left or right pectoral region.  For pacemaker-dependent patients, it is not recommended to perform an MRI scan if the right ventricular (RV) lead pacing capture threshold is greater than 2.0 V at 0.4 ms.  Patients whose device will be programmed to an asynchronous pacing mode when MRI SureScan is on must have no diaphragmatic stimulation at a pacing output of 5.0 V and at a pulse width of 1.0 ms.  It is not recommended to perform MRI scans during the lead maturation period (approximately 6 weeks).  Pace polarity parameters are set to Bipolar for programming MRI SureScan to On (Advisa MRI only); or a SureScan pacing system is implanted with a lead impedance value of ≥ 200 Ω and ≤ 1500 Ω.  Revo MRI patients must have pacing capture thresholds of ≤ 2.0 V at a pulse width of 0.4 ms and a SureScan pacing system that has been implanted for a minimum of 6 weeks.

    Potential complications

    Potential complications include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis.

    MRI SureScan IPGs: SureScan pacing systems have been designed to minimize potential complications in the MRI environment. Potential MRI complications include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or MR-induced stimulation on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse. 

    See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. See the appropriate product MRI SureScan Technical Manual before performing an MRI Scan. For further information, please call Medtronic at 1-800-328-2518 and/or consult www.medtronic.com or www.mrisurescan.com.

    Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_84705

    CRT IPGs & CRT ICDs ISW

    Brief statement: Medtronic CRT IPG and CRT ICD

    Indications

    CRT-Ps are indicated for NYHA Functional Class III and IV patients who remain symptomatic despite stable, optimal heart failure medical therapy and have a LVEF ≤ 35% and a prolonged QRS duration and for NYHA Functional Class I, II, or III patients who have a LVEF ≤ 50%, are on stable, optimal heart failure medical therapy if indicated and have atrioventricular block (AV block) that are expected to require a high percentage of ventricular pacing that cannot be managed with algorithms to minimize right ventricular pacing.  Optimization of heart failure medical therapy that is limited due to AV block or the urgent need for pacing should be done post implant. Rate adaptive pacing is provided for those patients developing a bradycardia indication who might benefit from increased pacing rates concurrent with increases in activity. Dual chamber and atrial tracking modes are indicated for patients who may benefit from maintenance of AV synchrony. Antitachycardia pacing (ATP) is indicated for termination of atrial tachyarrhythmias in patients with one or more of the above pacing indications.

    CRT-Ds are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias and for providing cardiac resynchronization therapy in heart failure patients on stable, optimal heart failure medical therapy if indicated, and meet any of the following classifications: New York Heart Association (NYHA) Functional Class III or IV and who have a left ventricular ejection fraction < 35% and a prolonged QRS duration. Left bundle branch block (LBBB) with a QRS duration > 130 ms, left ventricular ejection fraction < 30%, and NYHA Functional Class II. NYHA Functional Class I, II, or III and who have left ventricular ejection fraction ≤ 50% and atrioventricular block (AV block) that are expected to require a high percentage of ventricular pacing that cannot be managed with algorithms to minimize right ventricular pacing. Optimization of heart failure medical therapy that is limited due to AV block or the urgent need for pacing should be done post implant. Some CRT-Ds are also indicated for use in patients with atrial tachyarrhythmias, or those patients who are at significant risk for developing atrial tachyarrhythmias. The RV Lead Integrity Alert (LIA) feature is intended primarily for patients who have a Medtronic CRT-D device and a Sprint Fidelis lead (Models 6949, 6948, 6931, and 6930), based on performance data. The RV LIA feature may not perform as well with a St. Jude Riata/Durata lead or a Boston Scientific Endotak lead as it does when used with a Medtronic Sprint Fidelis lead. This is because different lead designs may have different failure signatures and conditions that may or may not be detected early by the RV LIA feature.

    A complete SureScan system is required for use in the MR environment.

    Contraindications

    CRT-Ps are contraindicated for concomitant implant with another bradycardia device and concomitant implant with an implantable cardioverter defibrillator. There are no known contraindications for the use of pacing as a therapeutic modality to control heart rate. The patient’s age and medical condition, however, may dictate the particular pacing system, mode of operation, and implant procedure used by the physician. Rate-responsive modes may be contraindicated in those patients who cannot tolerate pacing rates above the programmed Lower Rate. Dual chamber sequential pacing is contraindicated in patients with chronic or persistent supraventricular tachycardias, including atrial fibrillation or flutter. Asynchronous pacing is contraindicated in the presence (or likelihood) of competition between paced and intrinsic rhythms. Single chamber atrial pacing is contraindicated in patients with an AV conduction disturbance. Anti-tachycardia pacing (ATP) therapy is contraindicated in patients with an accessory antegrade pathway.

    CRT-Ds are contraindicated in patients experiencing tachyarrhythmias with transient or reversible causes including, but not limited to, the following: acute myocardial infarction, drug intoxication, drowning, electric shock, electrolyte imbalance, hypoxia, or sepsis; patients who have a unipolar pacemaker implanted, patients with incessant ventricular tachycardia (VT) or ventricular fibrillation (VF), and patients whose primary disorder is chronic atrial tachyarrhythmia with no concomitant VT or VF.

    Warnings and precautions 

    A complete SureScan system is required for use in the MR environment. Before performing an MRI scan, refer to the CRT-P or CRT-D MRI SureScan Technical Manual for  MRI-specific warnings and precautions. A complete SureScan pacing system includes a SureScan device with Medtronic SureScan leads or a Model 6725 pin plug for the right atrial port. To verify that components are part of a SureScan system, visit www.mrisurescan.com. For a CRT-D SureScan system, when a single coil SureScan defibrillation lead is used, a Medtronic DF-1 pin plug must be secured in the SVC port to make a complete SureScan defibrillation system. Any other combination may result in a hazard to the patient during an MRI scan.

    Changes in a patient’s disease and/or medications may alter the efficacy of the device’s programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.

    Certain programming and device operations may not provide cardiac resynchronization. Also for CRT-Ps, Elective Replacement Indicator (ERI) results in the device switching to VVI pacing at 65 ppm. In this mode, patients may experience loss of cardiac resynchronization therapy and/or loss of AV synchrony. For this reason, the device should be replaced prior to ERI being set. Use of the device should not change the application of established anticoagulation protocols.

    Patients and their implanted systems must be screened to meet the following requirements for MRI: no implanted lead extenders, lead adaptors, or abandoned leads; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history; a SureScan system implanted in the left or right pectoral region. Additionally, for patients whose device will be programmed to an asynchronous pacing mode when MRI SureScan is programmed to On, no diaphragmatic stimulation is present at a pacing output of 5.0 V and at a pulse width of 1.0 ms. For pacemaker-dependent patients, it is not recommended to perform an MRI scan if the right ventricular (RV) lead pacing capture threshold is greater than 2.0 V at 0.4 ms. A higher pacing capture threshold may indicate an issue with the implanted lead. 

    Potential adverse events

    Potential adverse events include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis. An additional complication for CRT-Ds is the acceleration of ventricular tachycardia.

    Potential MRI complications for the SureScan system include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or MRI induced currents on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse; spontaneous tachyarrhythmia occurring during the scan that is not detected and treated because tachyarrhythmia detection is suspended while MRI SureScan is programmed to On; potential for VT/VF induction when the patient is programmed to an asynchronous pacing mode during MRI SureScan; device heating resulting in tissue damage in the implant pocket or patient discomfort or both; or damage to the functionality or mechanical integrity of the device resulting in the inability of the device to communicate with the programmer. See the CRT-P or CRT-D MRI SureScan Technical Manual before performing an MRI Scan.

    See the appropriate CRT-P or CRT-D Device Manuals for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. See the appropriate CRT-P or CRT-D MRI SureScan Technical Manual before performing an MRI Scan. For further information, call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com or www.mrisurescan.com.

    CAUTION: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_84705

    Implantable Cardioverter Defibrillators ISW

    Brief statement: Medtronic ICD

    Indications 

    Implantable cardioverter defibrillators (ICDs) are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. Some ICDs are also indicated for use in patients with atrial tachyarrhythmias, or those patients who are at significant risk for developing atrial tachyarrhythmias.

    MRI Conditions for Use

    Medtronic SureScan ICD systems are MR Conditional, and as such are designed to allow patients to undergo MRI under the specified conditions for use.  Patients with MRI SureScan ICDs may be scanned using a horizontal field, cylindrical bore, clinical 1.5T or 3T MRI system for hydrogen proton imaging. When SureScan systems are programmed to On, the MRI SureScan feature allows the patient to be safely scanned while the device continues to provide appropriate pacing. A complete SureScan system, which is a SureScan device with appropriate SureScan lead(s), is required for use in the MR environment. When a single coil SureScan defibrillation lead is used, a Medtronic DF-1 pin plug must be secured in the SVC port to make a complete SureScan DF-1 defibrillation system. To verify that components are part of a SureScan system, visit http://www.mrisurescan.com/.  Any other combination may result in a hazard to the patient during an MRI scan.

    Contraindications

    ICDs are contraindicated in patients experiencing tachyarrhythmias with transient or reversible causes including, but not limited to, the following: acute myocardial infarction, drug intoxication, drowning, electric shock, electrolyte imbalance, hypoxia, or sepsis; patients who have a unipolar pacemaker implanted, patients with incessant ventricular tachycardia (VT) or ventricular fibrillation (VF), and patients whose primary disorder is chronic atrial tachyarrhythmia with no concomitant VT or VF.

    Warnings and precautions

    Changes in a patient's disease and/or medications may alter the efficacy of the device's programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.

    Patients and their implanted systems must be screened to meet the following requirements for MRI: no lead extenders, lead adaptors or abandoned leads present; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history and the system must be implanted in the left or right pectoral region.

    Potential adverse events

    Potential adverse events include, but are not limited to, body rejection phenomena, device migration, erosion through the skin, muscle and/or nerve stimulation, oversensing, failure to detect and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis. An additional complication for ICDs is the acceleration of ventricular tachycardia. Potential MRI complications for the SureScan system include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or MRI induced currents on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse; spontaneous tachyarrhythmia occurring during the scan that is not detected and treated because tachyarrhythmia detection is suspended while MRI SureScan is programmed to On; potential for VT/VF induction when the patient is programmed to an asynchronous pacing mode during MRI SureScan; device heating resulting in tissue damage in the implant pocket or patient discomfort or both; or damage to the functionality or mechanical integrity of the device resulting in the inability of the device to communicate with the programmer. See the MRI SureScan Technical Manual before performing an MRI Scan.

    See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com or http://www.mrisurescan.com/.

    CAUTION: Federal law (USA) restricts these devices to sale by or on the order of a physician.

    MAJ_84705

    Nearly 20 years of research and physician collaboration resulted in cardiac device algorithm innovations that help manage AF.

    Watch Dr. Amin Al-Ahmad walk through this history and discuss the AdaptivCRT™ algorithm, which reduces AF risk,19 and the Reactive ATP™ algorithm, which reduces AF duration.18

    To view the full webcast, visit medtronicacademy.com/globalgrandrounds.

    Respond to AF

    Exclusive feature to improve effective CRT delivery in the presence of AF

    EffectivCRT™ during AF algorithm

    Up to 16% increase in effective CRT delivery20

     

    The AdaptivCRT™ algorithm optimizes CRT pacing every minute whether AV conduction is normal, prolonged, or blocked. The EffectivCRT™ during AF algorithm automatically changes the pacing rate to increase effective CRT delivery during AF by up to 16%.20

     

    Dive deeper with Ruth Klepfer, senior research manager, as she explains how these two CRT algorithms work together to help manage AF in this short video.

    Treat AF

    Restore life‘s rhythm by unlocking potential through novel and efficient technology built on unmatched experience​.

    Learn how catheter-based ablation may be used to treat arrhythmias.

    See more
    This is an image of the Medtronic family of ablation catheters, including the Sphere-9™ ablation catheter, the PulseSelect™ pulsed field ablation system, and the Arctic Front Advance Pro™ cryoablation catheter.

    Continuous long-term cardiac monitoring

    Continued cardiac monitoring after an AF ablation with the Medtronic LINQ™ family of ICMs provides comprehensive data including AF burden, activity level, and heart rate variability. Insertable cardiac monitors remain the gold standard for the detection of AF recurrence and quantification of AF burden.†,21

    † Compared to intermittent monitoring.

    Find out more
    LINQ™ family of ICMs, including Reveal LINQ™ and LINQ II™ ICM, shown horizontally

    Resources

    Related links

    Follow us on social media.

    Stay up to date on product updates and events. 

    Medtronic 24-hour support

    Phone: 800-505-4636

    Products

    Filter by
    1. Pürerfellner H, Sanders P, Sarkar S, et al. Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors. Europace. 2018;20(Fl_3):f321–f328. doi: 10.1093/europace/eux272.
    2. Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(16):1713–1723. doi: 10.1016/j.jacc.2012.11.064.
    3. Boriani G, Manolis AS, Tukkie R, et al. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm. 2015;12(6):1192–1200. doi: 10.1016/j.hrthm.2015.02.017.
    4. Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–2245. doi: 10.1056/NEJMoa1602014.
    5. Kuck KH, Fürnkranz A, Chun KR, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016;37(38):2858–2865. doi: 10.1093/eurheartj/ehw285.
    6. Chun KRJ, Brugada J, Elvan A, et al. The impact of cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation on healthcare utilization and costs: an economic analysis from the FIRE AND ICE Trial. J Am Heart Assoc. 2017;6(8):e006043. doi: 10.1161/JAHA.117.006043.
    7. Passman R, Leong-Sit P, Andrei AC, et al. Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study. J Cardiovasc Electrophysiol. 2016;27(3):264–270. doi: 10.1111/jce.12864.
    8. Zuern CS, Kilias A, Berlitz P, et al. Anticoagulation after catheter ablation of atrial fibrillation guided by implantable cardiac monitors. Pacing Clin Electrophysiol. 2015;38(6):688–693. doi: 10.1111/pace.12625.
    9. Mascarenhas DAN, Farooq MU, Ziegler PD, Kantharia BK. Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding. Europace. 2016;18(6):799–806. doi: 10.1093/europace/euv350.
    10. Pothineni NVK, Amankwah N, Santangeli P, et al. Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2021;32(2):345–353. doi: 10.1111/jce.14864.
    11. Witkowski M, Bissinger A, Grycewicz T, Lubinski A. Asymptomatic atrial fibrillation in patients with atrial fibrillation and implanted pacemaker. Int J Cardiol. 2017;277:583–588. doi: 10.1016/j.ijcard.2016.10.097.
    12. Pürerfellner H, Gillis AM, Holbrook R, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol. 2004;27(7):983–992. doi: 10.1111/j.1540-8159.2004.00569.x.
    13. Ziegler PD, et al. Accuracy of atrial fibrillation detection in implantable pacemakers. Presented at HRS 2013 (PO02-08).
    14. QADoc DSN026170, Version 2.0, AT/AF duration performance comparison. Medtronic data on file.
    15. Boriani G, Deshmukh A, Brown ML Koehler J, Friedman PA. Understanding the incidence of AF in single chamber ICD patients: a real world analysis. EP Europace. 2017;19(S3):iii154. https://doi.org/10.1093/ehjci/eux151.022
    16. Chen S, Chen K, Tao Q, et al. Reduction of unnecessary right ventricular pacing by managed ventricular pacing and search AV+ algorithms in pacemaker patients: 12-month follow-up results of a randomized study. Europace. 2014;16(11):1595–1602.doi: 10.1093/europace/euu055.
    17. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;1107(23):2932–2937. doi: 10.1161/01.CIR.0000072769.17295.B1.
    18. Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. 2019;42(7):970–979. doi: 10.1111/pace.13696.
    19. Birnie D, Hudnall H, Lemke B, et al. Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm. 2017;14(12):1820–1825. doi: 10.1016/j.hrthm.2017.08.017.
    20. Plummer CJ, Frank CM, Bári Z, et al. A novel algorithm increases the delivery of effective cardiac resynchronization therapy during atrial fibrillation: The CRTee randomized crossover trial. Heart Rhythm. 2018;15(3):369–375. doi: 10.1016/j.hrthm.2017.10.026.
    21. Aguilar M, Macie L, Deyell MW, et al. The influence of monitoring strategy on assessment of ablation success and post-ablation atrial fibrillation burden assessment: Implications for practice and clinical trial design. Circulation. 2022;145(1):21–30. doi: 10.1161/CIRCULATIONAHA.121.056109.